The hepatitis C drug-marketing battle is heating up.
This morning, Abbvie (ABBV - Get Report) disclosed positive results from the remaining phase III studies of its all-oral hepatitis C regimen and said regulatory submissions would begin early in the second quarter. That's new and faster regulatory filing guidance and implies a commercial launch in the fourth quarter of this year, or perhaps sooner if FDA moves quickly to approve. [Abbvie's regimen has Breakthrough Therapy status.]
Gilead Sciences (GILD - Get Report) has already said it will seek regulatory approval for its fixed-dose combination therapy (Sovaldi+ledipasvir) in the first quarter.
Both the Abbvie and Gilead hepatitis C regimens are equally effective, with SVR (cure) rates in the high 90% range for both treatment naive and experienced patients. That means the choice for doctors and patients will likely come down to convenience and price. (Insurance companies may have a big say in the latter, too.)
The Gilead hepatitis C regimen consists of a single pill taken once per day. Simple. If ribavirin is required (which it may for some patients), that adds a second pill taken twice per day.
Abbvie's regimen requires two pills to be taken in the morning, plus a second pill at night. Again, if ribavirin is necessary, the patient takes two pills in the morning, and two pills at night. Remember, Enanta Pharmaceuticals (ENTA - Get Report) is Abbvie's hepatitis C partner.
Pricing? We don't know yet? Will Abbvie try to discount its therapy to make it more attractive? What will the insurance companies do with respect to access and prior authorization? For certain, the launch of these two competing hepatitis C therapies will be one of the most closely followed story lines in 2014.
Here is a snapshot of the Abbvie hepatitis C data announced today:
Very impressive results -- expected by investors for the most part -- but still impressive.
Meantime, the early prescription data on Gilead's Sovaldi launch continue to look amazing. Here's what ISI Group analyst Mark Schoenebaum emailed to clients this morning:
About 10 days ago I suggested based on early IMS data that GILD is likely to annihilate 2014 consensus numbers and that for 2014 I'm having a hard time getting to a number below $5B and that the actual 2014 reported US sales number could be $5B or even more. Sell side consensus hep C sales for 2014 are now at ~$3B and according to my most recent survey buy side expectation for 2014 US hep C sales is now ~$3.5B.
10/14/15 - 11:47 AM EDT
05/19/15 - 04:42 PM EDT
05/19/15 - 12:48 PM EDT
05/18/15 - 08:06 AM EDT
05/05/15 - 02:43 PM EDT
05/03/16 - 11:00 AM EDT
05/03/16 - 08:17 AM EDT
05/03/16 - 07:58 AM EDT
05/03/16 - 07:40 AM EDT
05/03/16 - 06:35 AM EDT
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Chris Versace, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.
Master swing trader Alan Farley uses his sophisticated software screens to review thousands of stocks each day for you, to find just the handful that meet his demanding criteria.